Employees: 981
Size Newland Pharmaceutical (301277.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $488M, the 3754th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥8.35 on 18 Nov 2026.
Performance Over six months the shares fell 22.5%, against -13.3% for the median peer and -20.0% for the China market (cap-weighted) — 6th lowest of 21 in its peer set.
Growth Revenue grew 9.4% over the last twelve months (peer median +12.8%); the operating margin is 11.5% (peer median 8.4%).
Valuation It trades at 3.5× enterprise value to sales against a peer median of 4.2× (9th cheapest of 21).
Price implies For today's price to make sense, revenue must grow about 9% a year for seven years (Req g). Recent delivered growth is +9%, so the hurdle is -0 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 4.9 points above its cost of capital (6.6% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥734M | CN¥670M | CN¥724M | CN¥648M | CN¥624M |
| Revenue growth | — | -7% | +12% | +4% | — |
| Gross profit | CN¥243M | CN¥210M | CN¥269M | CN¥242M | CN¥210M |
| EBITDA | n/a | CN¥177M | CN¥221M | CN¥194M | CN¥170M |
| Net income | CN¥93.0M | CN¥121M | CN¥174M | CN¥159M | CN¥132M |
| Free cash flow | CN¥41.6M | CN¥25.8M | CN¥30.2M | CN¥181M | CN¥8.84M |
| Capital expenditure | CN¥36.8M | CN¥101M | CN¥111M | CN¥96.5M | CN¥74.3M |
| Total debt | CN¥3.73M | CN¥5.69M | CN¥3.83M | CN¥2.72M | CN¥17.0M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 301277.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -15.5% | -2.6% | 4th lowest of 21 |
| 6-month return | -22.5% | -13.3% | 6th lowest of 21 |
| Distance from 52-week high | -39.7% | -35.5% | 9th lowest of 21 |
| Revenue growth (TTM) | +9.4% | +12.8% | 9th lowest of 21 |
| Operating margin | 11.5% | 8.4% | 8th highest of 21 |
| EV / Sales | 3.5× | 4.2× | 9th cheapest of 21 |
| Growth the price implies (Req g, 7 yrs) | 8.9% | -0.3% | 3rd most demanding of 9 |
| Growth delivered (Del g) | +9.1% | +3.9% | 2nd highest of 9 |
| Hurdle (Req g minus delivered) | -0.2 pp | -0.1 pp | 5th least demanding of 9 |
| ROIC minus cost of capital | +4.9 pp | -3.0 pp | 5th highest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Newland Pharmaceutical 301277.SZ | China | $488M | -22% | +9% | 11% | 3.5× | 8.9% | +9.1% |
| Nanjing Hicin Pharmaceutical 300584.SZ | China | $487M | -29% | +32% | 17% | 4.3× | 3.3% | -1.1% |
| Hefei Lifeon Pharmaceutical 003020.SZ | China | $486M | -21% | -1% | 10% | 2.0× | n/a | n/a |
| Tong Ren Tang Technologies 1666.HK | Hong Kong | $491M | -19% | -14% | 12% | 0.6× | -17.2% | +6.3% |
| Shandong Wohua Pharmaceutical 002107.SZ | China | $493M | -20% | -4% | 18% | 3.7× | 5.9% | -4.1% |
| Aarti Drugs AARTIDRUGS.NS | India | $494M | +34% | +15% | 11% | 1.8× | 22.1% | +3.5% |
| Shanghai MicuRx Pharmaceutical 688373.SS | China | $481M | -8% | +23% | -61% | 19.0× | n/a | n/a |
| Daewoong 003090.KS | South Korea | $495M | -28% | +6% | 11% | 0.9× | n/a | n/a |
| Jiangsu Lianhuan Pharmaceutical 600513.SS | China | $496M | -41% | +14% | 0% | 1.8× | n/a | n/a |
| Alpha Teknova TKNO | United States | $496M | +113% | +15% | -32% | 11.0× | n/a | n/a |
| REGENXBIO RGNX | United States | $480M | +22% | -5% | -120% | 3.1× | n/a | n/a |
| Henan Taloph Pharmaceutical Stock 600222.SS | China | $497M | -21% | -5% | 7% | 2.5× | 16.7% | +4.4% |
| Hansa Biopharma HNSA.ST | Sweden | $479M | +39% | +69% | -190% | 14.9× | -4.7% | +105.3% |
| Shanghai Fudan Forward S&T 600624.SS | China | $478M | 0% | -14% | -34% | 6.4× | n/a | n/a |
| SMS Pharmaceuticals SMSPHARMA.NS | India | $477M | +16% | +13% | 16% | 4.9× | n/a | n/a |
| Gyre Therapeutics GYRE | United States | $500M | -28% | +14% | -18% | 4.0× | n/a | n/a |
| Aquestive Therapeutics AQST | United States | $475M | -9% | +13% | -114% | 10.9× | n/a | n/a |
| Shanghai Xiao Fang Pharmaceutical 603207.SS | China | $503M | -17% | +10% | 39% | 4.8× | -5.4% | +7.6% |
| YungShin Global 3705.TW | Taiwan | $472M | +5% | -5% | 15% | 2.0× | -3.8% | +0.7% |
| Gujarat Themis Biosyn GUJTHEM.NS | India | $505M | +2% | +18% | 39% | 27.2× | n/a | n/a |
| ChengDa PharmaCeuticals 301201.SZ | China | $472M | -47% | +27% | -9% | 4.8× | n/a | n/a |